Epigenetic Therapy of Cancer

Preclinical Models and Treatment Approaches
Buch | Hardcover
X, 325 Seiten
2014 | 2014
Springer Berlin (Verlag)
978-3-642-38403-5 (ISBN)
106,99 inkl. MwSt
This book covers the translation of basic research and drug development to clinical applications in the treatment of solid tumors as well as hematologic malignancies and hemoglobinopathy. It examines both present and future clinical strategies.
The growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders is now being translated into treatment approaches that target the epigenetic defects pharmacologically. This book first presents the latest evidence regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail.

The fundamental role of epigenetic regulation for normal and disturbed all growth and differentiation.- Mouse models to study DNA methylation in cancer research.- Epigenetic regulation of normal hematopoietic development.- Epigenetic regulation of globin genes and disturbances in hemoglobinopathies.- DNA methylation abnormalities in hematopoietic disorders: biological significance and methodological approaches.- Epigenetic modifications mediated by the AML1/ETO and MLL leukemia fusion proteins.- Epigenetic abnormalities in lung cancer.- Pharmacodynamic Responses to DNA Methyltransferase Inhibition.- Histone Methyltransferases: Opportunities in Cancer Drug Discovery.- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.- Clinical Implications of Epigenetic Alterations in Lung Cancer.- Epigenetic disturbances in colorectal cancer.- Epigenetic Therapies in Solid Tumours: from preclinical models to clinical trial results.

From the reviews:
"This new book covers the timely topic of epigenetic therapy. ... The combination of articles describing the basic science framework of epigenetics and the detailed summaries of clinical trials with epigenetic drugs is attractive for a wide readership, ranging from medical students to scientists who are interested in translational studies to clinicians who work for the direct benefit of cancer patients. ... This high-quality book is an excellent overview of the current success and future promise of epigenetic therapy." (Gerd Pfeifer, Doody's Book Reviews, May, 2014)

Erscheint lt. Verlag 15.1.2014
Zusatzinfo X, 325 p. 48 illus., 14 illus. in color.
Verlagsort Berlin
Sprache englisch
Maße 155 x 235 mm
Gewicht 616 g
Themenwelt Medizinische Fachgebiete Innere Medizin Hämatologie
Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Studium 2. Studienabschnitt (Klinik) Humangenetik
Schlagworte carcinoma • Chromatin • DNA Methylation • gene therapy • Histone Organisation • Krebstherapie • Myelodysplasia
ISBN-10 3-642-38403-X / 364238403X
ISBN-13 978-3-642-38403-5 / 9783642384035
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Wie bewerten Sie den Artikel?
Bitte geben Sie Ihre Bewertung ein:
Bitte geben Sie Daten ein:
Mehr entdecken
aus dem Bereich
Hämatologie und Internistische Onkologie

von Dietmar P. Berger; Monika Engelhardt; Justus Duyster

Buch | Softcover (2023)
ecomed-Storck GmbH (Verlag)
129,99